Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | DVL1 | O14640 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3557611 | 0.88 | POLB (0.65) | SMN1; SMN2POLBNPC1RAB9AMAPT | |
| SCHEMBL3552720 | 0.88 | DVL1 (0.67) | POLBRAB9AMAPTMAPK1DVL1 | |
| SCHEMBL3561252 | 0.86 | NOTUM (0.55) | POLBNPC1RAB9ADVL1KMT2A | |
| SCHEMBL3556566 | 0.86 | SERPINE1 (0.53) | SMN1; SMN2NPC1RAB9AMAPTDVL1 | |
| SCHEMBL3559202 | 0.83 | DVL1 (0.47) | SMN1; SMN2POLBNPC1RAB9AMAPT | |
| SCHEMBL3565134 | 0.83 | KDM4E (0.58) | SMN1; SMN2POLBMAPTDVL1KMT2A | |
| SCHEMBL3556282 | 0.82 | KMT2A (0.59) | SMN1; SMN2POLBNPC1RAB9AMAPT | |
| SCHEMBL3558904 | 0.80 | HCAR2 (0.56) | SMN1; SMN2POLBNPC1RAB9AKMT2A | |
| SCHEMBL3559573 | 0.80 | MEN1 (0.50) | POLBNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL3561950 | 0.79 | POLB (0.53) | SMN1; SMN2POLBRAB9AMAPTDVL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732452-B2 | Thiophene derivatives which are HM74A agonists | HOFFMANN-LA ROCHE INC. (US) | 2010-06-08 | — | — | US | claimed |
| EP-1931651-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-18 | — | — | EP | claimed |
| US-20070161650-A1 | Novel thiophene derivatives which are HM74A agonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-12 | — | — | US | claimed |
| WO-2007039482-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | claimed |
| US-20070072873-A1 | Novel thiophene derivatives which are HM74A agonists | HOFFMANN-LA ROCHE INC. | 2007-03-29 | — | — | US | claimed |
| US-7732452-B2 | Thiophene derivatives which are HM74A agonists | HOFFMANN-LA ROCHE INC. (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1931651-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| US-20070161650-A1 | Novel thiophene derivatives which are HM74A agonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-12 | — | — | US | disclosed |
| WO-2007039482-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072873-A1 | Novel thiophene derivatives which are HM74A agonists | HOFFMANN-LA ROCHE INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072873-A1 | Novel thiophene derivatives which are HM74A agonists | GPR84, GPR174, MRGPRX1 | SMN1; SMN2 3043/4885POLB 4319/4885NPC1 1082/4885 |
| US-20070161650-A1 | Novel thiophene derivatives which are HM74A agonists | GPR84, GPR174, MRGPRX1 | SMN1; SMN2 3043/4885POLB 4319/4885NPC1 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.